|
Vioxx Redux: FDA on the Sidelines as Marketing Subsumes Evidence: Surviving Sepsis-NEJM |
|
|
|
|
Saturday, 21 October 2006 |
|
Lilly's aggressive marketing of Xigris does indeed epitomize the worst ofthis industry's mission. |
|
Read more...
|
|
|
Press Coverage of Xigris NEJM article |
|
|
|
|
Thursday, 19 October 2006 |
|
"Academic officials acknowledged in the published guidelines that Lilly gave more than 90 percent of $861,000 in grants for the campaign and medical recommendations. About a fifth of the 46 guidelines writers acknowledged previously taking money from Eli Lilly for speaking, consulting or research." |
|
Read more...
|
|
|
Former FDA Chief Lied Under Oath Is Charged With Financial Conflict of Interest |
|
|
|
|
Tuesday, 17 October 2006 |
Below the New York Times provides a summary of Crawford's selective disclosure and concealment of his financial holdings while he was Commissioner, noting Crawford's ignoble tenure: |
|
Read more...
|
|
|
Industry Influence: FDA "Critical Path"/ Biased Research: BMJ / NIH: still smoke & mirrors |
|
|
|
|
Saturday, 07 October 2006 |
|
The battle lines were drawn between those who recognize the corrosive effect that the pharmaceutical industry is having on the safety and integrity of medicine and medical research, and the powerful stakeholders--the pharmaceutical-academic industrial complex. |
|
Read more...
|
|
|
Debate: PhRMA and its relations with Gov, Academia, Doctors and Consumers_Oct 4-5 |
|
|
|
|
Tuesday, 03 October 2006 |
|
Two especially timely conferences focus on MEDICINE AND THE LAW:
|
|
Read more...
|
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
| Results 55 - 63 of 142 |